Microbiome Drug Development

Online Symposium

24 September 2024 | Online, BST (UTC+1)

Bringing together key opinion leaders from across the globe for focused discussions on microbiome discovery & therapeutic development

Key Topics Covered

Morning Session: Advancing Microbiome Discovery – Novel Technologies, Analysis & Data-Driven Approaches

  • Identification and characterization of bacterial species associated with different disease areas & responses to therapeutics
  • Human microbiome analysis & microbiome profiling:
       » NGS methods
       » Single- cell genomics
  • Data driven approaches to microbiome discovery: AI/ML; advanced bioinformatics tools and technologies

Afternoon Session: Microbiome-based Therapeutic Development

  • Therapeutics development case studies:
       » Oncology & immune-oncology
       » Inflammatory bowel disease
       » Kidney Diseases
       » TB infection
  • Standardisation of manufacturing processes

Benefits of Attending

  • Meet with global key innovators in microbiome drug development. This highly-focused online symposium will bring together thought leaders attendees from pharma & biotech companies and academic institutions. 2024 attendees include: Chief Technology Officer, Adiso Therapeutics; Microbiome Group Leader, MHRA and Professor, University of Florence
  • Hear about the latest developments in microbiome discovery. This highly anticipated event brings together key opinion leaders to discuss novel technologies, human microbiome analysis & microbiome profiling techniques and data-driven approaches to microbiome discovery such as AI/ML 
  • Discuss the latest advancements in microbiome-based therapeutic development. Learn about exploring the development of live bacterial therapies, targeting & modulating the microbiome for therapeutics purposes and hear case studies from various therapeutic areas   
  • Followed by the release of the ‘Harnessing Microbiome Drug Discovery & Development report detailing key insights, methodologies, and emerging trends discussed during the event for leveraging microbiome drug development effectively



Latest Resources

Blood Biomarkers Signal Increased Risk of Alzheimer's & MND After Multiple Rugby Concussions

Results that show rugby players that have sustained multiple concussions present with markers of neurodegenerative disease development.

Life Science Players Join €23m European Project for Precision Medicine, PRECISEU

The project will bring together life science institutions across European nations in the interest of expanding development of and access to advanced therapy medicinal products.

Feinstein Institutes Links Blood Biomarkers to Psychosis in Alzheimer's Patients

The global aging population means that rates of Alzheimer's disease are expected to reach 14 million patients by 2060, many of whom will experience psychosis.

ZERO Precision Medicine Programme Reports Outstanding Efficacy in High-Risk Paediatric Cancers

The first-of-its-kind trial presents a positive outlook for cancer types with historically poor survival rates.

Hope for New Prognostic Biomarkers & Therapeutic Options From Tumour Metabolism-Targeting Breast Cancer Study

Understanding the interplay between the tumour microenvironment and immunometabolic states could unlock a wealth of therapeutic targets and biomarkers.

New Zika-Specific Synthetic Biomarker Can Differentiate From Dengue Virus

A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease.

Meet Our Expert Speakers

Microbiome Drug Development Online Symposium again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Confirmed speakers include:

Amedeo Amedei
Full Professor,
University of Florence
Bharat Dixit
Chief Technology Officer,
Adiso Therapeutics
Chrysi Sergaki
Microbiome Group Leader,
MHRA
Lesley Hoyles
Professor of Microbiome and Systems Biology,
Nottingham Trent University
Mona Bajaj
Associate Professor,
University College London
Robert Mills
Scientific Director,
Piton Therapeutics
Sanjib Bhakta
Professor of Molecular Microbiology and Biochemistry & Assistant Dean (Internationalisation and Partnership),
University College London

Register Your Interest

Submit your details and a member of our team will be in touch